INS and chronic myelogenous leukemia, BCR-ABL1 positive: In a clinical observation of seven diabetic chronic myeloid leukaemia patients being treated with imatinib, six patients showed improvement in fasting blood glucose concentration which led to a reduction of their insulin dosage or oral antidiabetic drugs (Breccia et al., 2004).